CA - Aurinia: Updated Lupkynis Label Should Keep Sales Growth Momentum Going

2024-04-30 13:00:10 ET

Summary

• Aurinia Pharmaceuticals Inc. full-year 2023 sales of Lupkynis increased by 53% year over year to $158.5 million.
• Updated label provides several advantages for sales of Lupkynis going forward, like no need for monthly kidney monitoring 1-year after treatment, lactation note for women and display of 3-year efficacy.
• Besides label expansion of Lupkynis, other shareholder generating measures enacted were the $150 million share repurchase program and the cutting of the AUR200 and AUR300 programs to conserve cash.
• Two data readouts are expected to be released in 2027 that could boost shareholder value; They are the real-world scenario study of patients first given Lupkynis for LN and then another study targeting patients between the ages of 12 to 18.

Aurinia Pharmaceuticals Inc. ( AUPH ) has been continuing to see growth in sales of its drug Lupkynis, which has been approved by the FDA and European Medicines Agency [EMA] for the treatment of patients with lupus nephritis [LN]. The last time I spoke about this biotech was through a Seeking Alpha article entitled " Aurinia Pharmaceuticals: Still In The Game With Lupkynis Sales. "...

For further details see: